Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab Induction Therapy in Ulcerative Colitis (FIGARO UC 302)
NCT03259308Phase 3Terminated
- Sponsor
- Takeda
- Start
- Dec 2017
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in ulcerative colitis (UC) (3 arms), sponsored by Takeda. Primary endpoint: Number of Participants With Remission Based on Composite Score at 12 weeks. Started Dec 2017; status: terminated.
02
Drugs
ontamalimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03259308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259308.